# Viatris Inc. (VTRS) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $16.88, market value $19.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Viatris Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 1.3×**. Each dollar of revenue is priced at 1.3×.
- **Price / book: 1.3×**. The shares trade at 1.3× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 12.0×**. Enterprise value is 12.0× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 10.1%** (5-yr avg 20.9%). Free cash flow equals 10.1% of the market value, below its five-year average of 20.9%, so the shares are pricier on cash than usual. Above 5% is generally attractive.

## Profitability
- **Gross margin: 34.9%**. Viatris Inc. keeps 34.9% of revenue after the direct cost of what it sells.
- **Operating margin: -0.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -24.7%**. The company reported a net loss over the last twelve months.
- **Return on equity: -23.9%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -0.2%**. Return on all capital, debt included, is -0.2%: close to or below the cost of capital, so growth may not create value.

## Growth
- **Revenue growth (1 yr): -3.0%** (3-yr -4.2%/yr, 5-yr 3.8%/yr). Revenue fell 3.0% over the last year, against 3.8% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -466.0%**. Earnings per share fell 466.0%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -9.3%/yr**. Free cash flow has compounded at -9.3% a year over three years.

## Financial health
- **Debt to equity: 0.98**. Debt is 0.98 times equity, moderate leverage.
- **Net debt / EBITDA: 4.8×**. It would take 4.8 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Interest coverage: -0.2×**. Operating profit covers interest only -0.2×: fragile.
- **Altman Z-score: 1.22**. A Z-score of 1.22 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 2.84%** ($0.48 per share, trailing). Viatris Inc. yields 2.84%, a modest yield more typical of a growth-oriented payer.
- **Consecutive years of increases: 5**. 5 straight years of increases.

## Price and momentum
- **Total return (1 yr): 67.9%** (YTD 37.7%, 3-mo 6.3%). The shares are up 67.9% over twelve months including dividends.
- **From 52-week high: -8.2%** (79.0% above the low). Trading 8% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 0.70** (volatility 32%). Beta of 0.70 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=VTRS · Page: https://foliofundamentals.com/stocks/vtrs

Not investment advice.